Market capitalization | $8.41m |
Enterprise Value | $1.29m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.38 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-7.49m |
Free Cash Flow (TTM) Free Cash Flow | $-6.82m |
Cash position | $7.12m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Monopar Therapeutics Inc forecast:
3 Analysts have issued a Monopar Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -7.49 -7.49 |
26%
26%
|
EBIT (Operating Income) EBIT | -7.49 -7.49 |
26%
26%
|
Net Profit | -7.12 -7.12 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Monopar Therapeutics, Inc. is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Head office | United States |
CEO | Chandler Robinson |
Employees | 10 |
Founded | 2014 |
Website | www.monopartx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.